Prevention-effective adherence trajectories among transgender women indicated for PrEP in the United States: a prospective cohort study.
Group-based multi-trajectory modeling
HIV prevention
Pre-exposure prophylaxis
Transgender women
United States
Journal
Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
02
11
2021
revised:
18
03
2022
accepted:
30
03
2022
pubmed:
11
4
2022
medline:
7
6
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
Adherence to pre-exposure prophylaxis (PrEP) during periods of PrEP-indication (i.e., prevention-effective adherence) is critical for preventing HIV. We sought to describe factors associated with prevention-effective adherence trajectories among transgender women (TW) to inform PrEP implementation strategies. Using data from The LITE American Cohort (n = 728), we performed group-based multi-trajectory modeling (GBMTM) to identify clusters of TW with similar trajectories of PrEP adherence and indication, and sociodemographic, biobehavioral, and structural correlates of each trajectory. We identified five trajectories: (1) consistent indication/no PrEP (15.3%), (2) initial indication/no PrEP (47.1%), (3) declining indication/discontinued PrEP (9.5%), (4) consistent indication/PrEP adherent (18.5%), and (5) increasing indication/initiated PrEP (9.6%). TW diagnosed with an STI were more likely to follow a consistent indication/no PrEP trajectory compared to consistent indication/PrEP adherent trajectory (adjusted Relative Risk Ratio [aRRR], 2.54; 95% confidence interval [CI], 1.16-5.57). TW who experienced homelessness were more likely to follow PrEP discontinuation and initiation trajectories relative to PrEP adherence (aRRR, 2.71; 95% CI, 1.10-6.70 and 2.83; 95% CI, 1.13-7.05, respectively). Over a quarter of TW followed trajectories suggestive of prevention-effective adherence, while 15% did not initiate PrEP despite consistent indication. Findings highlight missed opportunities for PrEP engagement at STI diagnosis and suggest structural interventions addressing housing instability may improve prevention-effective adherence among TW.
Identifiants
pubmed: 35398255
pii: S1047-2797(22)00050-3
doi: 10.1016/j.annepidem.2022.03.016
pmc: PMC9167788
mid: NIHMS1796200
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-31Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : UG3 AI133669
Pays : United States
Organisme : NIAID NIH HHS
ID : UH3 AI133669
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH067127
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI117970
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI073961
Pays : United States
Organisme : NIMH NIH HHS
ID : F31 MH124582
Pays : United States
Organisme : NICHD NIH HHS
ID : P2C HD050924
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH114715
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Références
Prev Sci. 2017 Jul;18(5):505-516
pubmed: 28101813
Epidemiol Rev. 2018 Jun 1;40(1):27-39
pubmed: 29554240
Lancet HIV. 2018 Mar;5(3):e136-e145
pubmed: 29467098
JMIR Res Protoc. 2019 Oct 3;8(10):e14704
pubmed: 31584005
Soc Sci Med. 2019 Apr;226:225-235
pubmed: 30674436
J Community Health. 2019 Dec;44(6):1193-1203
pubmed: 31317438
AIDS. 2021 Mar 1;35(3):524-526
pubmed: 33507011
AIDS Behav. 2017 Dec;21(12):3312-3327
pubmed: 29138982
PLoS One. 2021 Jan 19;16(1):e0244226
pubmed: 33465090
Lancet Infect Dis. 2013 Mar;13(3):214-22
pubmed: 23260128
Glob Public Health. 2016 Aug-Sep;11(7-8):1060-75
pubmed: 26963756
J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21105
pubmed: 27760683
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):131-140
pubmed: 31180995
J Acquir Immune Defic Syndr. 2021 May 1;87(1):639-643
pubmed: 33512848
Soc Sci Med. 2019 Jun;230:280-294
pubmed: 31035207
J Int AIDS Soc. 2020 Jun;23 Suppl 3:e25539
pubmed: 32602642
Curr HIV/AIDS Rep. 2017 Aug;14(4):141-152
pubmed: 28752285
AIDS Behav. 2017 May;21(5):1236-1246
pubmed: 28108878
Ann Epidemiol. 2021 Dec;64:102-110
pubmed: 34563567
LGBT Health. 2018 Oct;5(7):387-390
pubmed: 30272493
JMIR Res Protoc. 2021 Apr 26;10(4):e29152
pubmed: 33900202
Stat Methods Med Res. 2018 Jul;27(7):2015-2023
pubmed: 29846144
AIDS Care. 2020 May;32(5):585-593
pubmed: 31482726
AIDS Behav. 2018 Nov;22(11):3673-3680
pubmed: 29754268
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095
Arch Sex Behav. 2021 Jan;50(1):1-6
pubmed: 33507424
Lancet HIV. 2015 Dec;2(12):e512-9
pubmed: 26614965